Concepedia
Statistics
Publications
12
Citations
675
H-Index
11
Active since
1997
Affiliations
Eli Lilly (Germany)(Current)
Eli Lilly (United States)
Universitat Autònoma de Barcelona
Freie Universität Berlin
Goethe University Frankfurt
U. Ohnmacht is an author at Eli Lilly (Germany) specializing in medicine, oncology, and molecular oncology.
Publications per year
1997–2018
First-in-human study of LY3039478, an oral Notch signaling inhibitor in advanced or metastatic cancer
Christophe Massard, A. Ázaro, Jean‐Charles Soria et al. · Annals of Oncology · 2018 · 163 citations · Full text
Medicine, Oncology, Pharmacology +14
Phase II study of gemcitabine as first-line chemotherapy in patients with advanced or metastatic breast cancer
K. Possinger, M. Kaufmann, Robert Coleman et al. · Anti-Cancer Drugs · 1999 · 131 citations
Medicine, Oncology, Pharmacology +15
Promoter methylation of RASSF1A, RARβ and DAPK predict poor prognosis of patients with malignant mesothelioma
Jürgen R. Fischer, U. Ohnmacht, Norman Rieger et al. · Lung Cancer · 2006 · 95 citations
Medicine, Cancer Biology, Oncology +16
Prognostic significance of RASSF1A promoter methylation on survival of non-small cell lung cancer patients treated with gemcitabine
Jürgen R. Fischer, U. Ohnmacht, Norman Rieger et al. · Lung Cancer · 2006 · 75 citations
Medicine, Genetics, Oncology +16
Preclinical analyses and phase I evaluation of LY2603618 administered in combination with Pemetrexed and cisplatin in patients with advanced cancer
Emiliano Calvo, Victor J. Chen, Mark S. Marshall et al. · Investigational New Drugs · 2014 · 57 citations
Medicine, Oncology, Pharmacology +7
1–5 of 12